Yahoo
NYSE - Delayed Quote USD

Johnson & Johnson (JNJ)

275.23 -3.20 (-1.15%)
At close: September 4 at 4:00:02 PM EDT
278.51 +3.28 (+1.19%)
After hours: September 4 at 7:59:34 PM EDT
Trade JNJ on Coinbase
Chart Range Bar
Loading chart for JNJ

What's happening with JNJ?

25m ago
Powered by Yahoo Scout

Johnson & Johnson (JNJ) has seen a 60% stock surgeover the past year, despite facing significant challenges, including 55.7%sales decline from STELARA biosimilars. The company continues to project strong operational sales and has raised its full-year guidance to $100.6 billion.

Powered by Yahoo Scout
  • Previous Close 278.43
  • Open 275.13
  • Bid 275.37 x 10000
  • Ask 279.00 x 20000
  • Day's Range 274.75 - 277.80
  • 52 Week Range 173.33 - 281.07
  • Volume 3,878,977
  • Avg. Volume 7,847,438
  • Market Cap (intraday) 663.276B
  • Beta (5Y Monthly) 0.23
  • PE Ratio (TTM) 32.27
  • EPS (TTM) 8.53
  • Earnings Date Oct 13, 2026
  • Forward Dividend & Yield 5.36 (1.93%)
  • Ex-Dividend Date Aug 25, 2026
  • 1y Target Est 275.64

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

www.jnj.com

138,200

Full Time Employees

December 28

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

JNJ
35.13%
S&P 500 (^GSPC)
12.75%

1-Year Return

JNJ
57.44%
S&P 500 (^GSPC)
18.71%

3-Year Return

JNJ
86.77%
S&P 500 (^GSPC)
70.93%

5-Year Return

JNJ
80.80%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 25.31B
Earnings 5.53B
Profit Margin 21.86%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5B
10B
15B
20B
25B
21.0%
21.2%
21.4%
21.6%
21.8%

Analyst Insights

View More

Analyst Price Targets

190.00 Low
275.64 Average
275.23 Current
320.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/2/2026
Analyst UBS
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 280 -> 320

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    21.48%

  • Return on Assets (ttm)

    8.60%

  • Return on Equity (ttm)

    25.74%

  • Revenue (ttm)

    97.93B

  • Net Income Avi to Common (ttm)

    21.04B

  • Diluted EPS (ttm)

    8.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.76B

  • Total Debt/Equity (mrq)

    57.71%

  • Levered Free Cash Flow (ttm)

    16.89B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: